Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | HPGD | P15428 | 5/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19425675 | 0.84 | MEN1 (0.38) | KMT2AMEN1CYP1A2ELANEP2RY2 | |
| SCHEMBL23229065 | 0.79 | KMT2A (0.35) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL10183369 | 0.78 | KDM4E (0.38) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL10005837 | 0.77 | BRD4 (0.42) | KMT2AMEN1CYP1A2ELANEPARP1 | |
| SCHEMBL24421336 | 0.75 | MEN1 (0.40) | KMT2AMEN1CYP1A2ELANEPARP1 | |
| SCHEMBL32673394 | 0.75 | KMT2A (0.51) | KMT2AMEN1CYP1A2PIK3CDALDH1A1 | |
| SCHEMBL15357740 | 0.74 | MGLL (0.36) | KMT2AMEN1ELANEALDH1A1KDM4E | |
| SCHEMBL23229059 | 0.73 | ALDH1A1 (0.33) | KMT2AMEN1CYP1A2ELANEALDH1A1 | |
| SCHEMBL122923 | 0.73 | KDM4E (0.41) | KMT2AELANEALDH1A1HSD17B10KDM4E | |
| SCHEMBL10129561 | 0.72 | BRD4 (0.37) | CYP1A2ELANEALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11761007-B2 | Production of unnatural nucleotides using a CRISPR/Cas9 system | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-19 | — | — | US | disclosed |
| US-11761007-B2 | Production of unnatural nucleotides using a CRISPR/Cas9 system | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-19 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210071240-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-03-11 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070275914-A1 | Therapeutic Compositions | BANK OF AMERICA, N.A. | 2007-11-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | KMT2A 1675/4885MEN1 1598/4885CYP1A2 4804/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | KMT2A 2687/4885MEN1 790/4885CYP1A2 4588/4885 |
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | KMT2A 1350/4885MEN1 4796/4885CYP1A2 4840/4885 |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | KMT2A 3588/4885MEN1 4518/4885CYP1A2 3132/4885 |
| US-20070275914-A1 | Therapeutic Compositions | AGO2, EXOSC5, RNASE1 | KMT2A 1598/4885MEN1 3331/4885CYP1A2 4371/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | KMT2A 2744/4885MEN1 2869/4885CYP1A2 4881/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | KMT2A 1975/4885MEN1 630/4885CYP1A2 3847/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | KMT2A 1129/4885MEN1 1993/4885CYP1A2 3615/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | KMT2A 1569/4885MEN1 939/4885CYP1A2 2684/4885 |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | SLC35B2, SLC29A2, PNP | KMT2A 3588/4885MEN1 4518/4885CYP1A2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.